Cellular-Based Immunotherapies for Patients with Glioblastoma Multiforme

Treatment of patients with glioblastoma multiforme (GBM) remains to be a challenge with a median survival of 14.6 months following diagnosis. Standard treatment options include surgery, radiation therapy, and systemic chemotherapy with temozolomide. Despite the fact that the brain constitutes an imm...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Xun, Stockhammer, Florian, Schmitt, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3299309/
https://www.ncbi.nlm.nih.gov/pubmed/22474481
http://dx.doi.org/10.1155/2012/764213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3299309/
https://www.ncbi.nlm.nih.gov/pubmed/22474481
http://dx.doi.org/10.1155/2012/764213

Ejemplares similares